Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Circulation

• Publication date

  2005-03-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.0000157138.02645.11PMID 15738352
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The difference between clopidogrel responsiveness and posttreatment platelet reactivity.

  2005cited by this paper
• Pharmacokinetics of clopidogrel after administration of a high loading dose

  2004cited by this paper
• A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel

  2004cited by this paper
• 1100-62 Superior early platelet inhibition by 600mg clopidogrel loading in elective stenting

  2004cited by this paper
• Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction

  2004cited by this paper
• Platelet activation in myocardial ischemic syndromes

  2004cited by this paper
• A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.

  2004cited by this paper
• Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis

  2004cited by this paper
• Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator‐stimulated phosphoprotein phosphorylation

  2003cited by this paper
• Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

  2003cited by this paper
• The early antiplatelet effects of clopidogrel loading for coronary stenting and the long‐term stability of inhibition

  2003cited by this paper
• Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity

  2003cited by this paper
• The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting.

  2002cited by this paper
• Death Following Creatine Kinase-MB Elevation After Coronary Intervention: Identification of an Early Risk Period: Importance of Creatine Kinase-MB Level, Completeness of Revascularization, Ventricular Function, and Probable Benefit of Statin Therapy

  2002cited by this paper
• Effect of Eptifibatide for Acute Coronary Syndromes: Rapid Versus Late Administration—Therapeutic Yield on Platelets (The EARLY Platelet Substudy)

  2002cited by this paper
• The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting

  2002cited by this paper
• Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality.

  2002cited by this paper
• Effect of clopidogrel on bleeding after coronary artery bypass surgery

  2001cited by this paper
• Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

  2001cited by this paper
• Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department.

  2000cited by this paper
• Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.

  2000cited by this paper
• Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting.

  2000cited by this paper
• Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.

  1991cited by this paper

• P2Y12 inhibitor loading time before elective PCI and the prevention of myocardial necrosis.

  2023cites this paper
• Understanding clopidogrel resistance: Mechanisms, detections, implications and surmount the clopidogrel resistant in order to potential solutions

  2023cites this paper
• Eptifibatide bridging therapy for staged carotid artery stenting and cardiac surgery: Safety and feasibility

  2022cites this paper
• A Systematic Review of Clopidogrel Resistance in Vascular Surgery: Current Perspectives and Future Directions.

  2022cites this paper
• Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials

  2022cites this paper
• A randomized trial of clopidogrel versus ticagrelor after off-pump coronary bypass.

  2022cites this paper
• Bivalirudin and sirolimus co-eluting coronary stent: Potential strategy for the prevention of stent thrombosis and restenosis.

  2021cites this paper
• 2020 Focused Update of the 2012 Guidelines of the Taiwan Society of Cardiology for the Management of ST-Segment Elevation Myocardial Infarction.

  2020cites this paper
• Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.

  2020cites this paper
• An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation

  2020cites this paper
• First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition: Comparison With Chewed and Swallowed Acetylsalicylic Acid.

  2020cites this paper
• Platelet Function Testing in Clinical Research Trials

  2019cites this paper
• Addition of Low Molecular Weight Heparin to Antiplatelet in Patients with Stroke Ineligible for Thrombolysis: Can it Improve Outcome?

  2019cites this paper
• Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: A single-center randomized controlled trial.

  2019cites this paper
• Clinical Tests of Platelet Function

  2019cites this paper
• Modifying effect of diabetes on the short-term effect of clopidogrel in patients with myocardial infarction

  2018cites this paper
• Assessing a 600-mg Loading Dose of Clopidogrel 24 Hours Prior to Pipeline Embolization Device Treatment

  2018cites this paper
• Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome.

  2018cites this paper
• Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?

  2018cites this paper
• 2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome.

  2018cites this paper
• Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy?

  2018cites this paper
• Impact of CYP2C19 Polymorphism on Antiplatelet Potency of Prasugrel 5 and 10 mg Daily Maintenance

  2018cites this paper
• A Critical Review on Metallic Glasses as Structural Materials for Cardiovascular Stent Applications

  2018cites this paper
• Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention

  2018cites this paper
• Assessing the efficacy of aspirin and clopidogrel in patients with acute coronary syndromes

  2018cites this paper
• Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?

  2018cites this paper
• Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study

  2018cites this paper
• CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans

  2017cites this paper
• Monitoring of Antiplatelet Therapy

  2017cites this paper
• Safety and Efficacy of a 600-mg Loading Dose of Clopidogrel 24 Hours Before Pipeline Embolization Device Treatment.

  2017cites this paper
• Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals

  2017cites this paper
• of Emergency Medicine : Integrating Emergency Care with Population Health Title Balancing Potency of Platelet Inhibition with Bleeding Risk in the Early Treatment of Acute Coronary Syndrome

  2017cites this paper
• The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics

  2017cites this paper
• Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors

  2017cites this paper
• Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease

  2016cites this paper
• The Dogged Search for Cryptic Effects of Ticagrelor: Wishful Thinking or Real Benefits Beyond P2Y12 Inhibition?

  2016cites this paper
• Duration of Dual Antiplatelet Therapy After Coronary Stenting.

  2016cites this paper
• Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.

  2016cites this paper
• Prolonged High‐Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta‐Analysis

  2016cites this paper
• The Role of Platelet Function Testing in the Development of Platelet Inhibitors

  2016cites this paper
• Markers of Platelet Function

  2016cites this paper
• Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention

  2016cites this paper
• Clopidogrel Resistance: Current Issues

  2016cites this paper
• Platelet-to-lymphocyte ratio but not neutrophil-to-lymphocyte ratio predicts high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndrome

  2016cites this paper
• P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

  2015cites this paper
• Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy.

  2015cites this paper
• Platelet reactivity following high loading doses of clopidogrel in patients undergoing primary percutaneous coronary angioplasty: A pilot study: The CArdiovascular Percutaneous Intervention TriAL Group (CAPITAL) LOAD Study

  2015cites this paper
• Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients.

  2015cites this paper
• Bivalirudin versus heparin in patients with acute myocardial infarction: A meta‐analysis of randomized trials

  2015cites this paper
• Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls

  2015cites this paper
• Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis

  2014cites this paper
• Pharmacodynamics- and Pharmacogenetics-Guided Antiplatelet Therapy

  2014cites this paper
• Significance of antiplatelet therapy in emergency myocardial infarction treatment

  2014cites this paper
• Effect of clopidogrel use post coronary artery bypass surgery on graft patency.

  2014cites this paper
• Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response – The TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial

  2014cites this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cites this paper
• Antiplatelet response to aspirin and clopidogrel in patients with coronary artery disease undergoing percutaneous coronary intervention

  2014cites this paper
• Clopidogrel resistance: the way forward.

  2014cites this paper
• Detection of clopidogrel resistance using ADP induced aggregometry with specific inhibitor PGE1.

  2014cites this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cites this paper
• Influence of Race and Sex on Thrombogenicity in a Large Cohort of Coronary Artery Disease Patients

  2014cites this paper
• Clinical and economic studies of eptifibatide in coronary stenting

  2014influential citation
• Clinical and economic studies of eptifibatide in coronary stenting

  2014cites this paper
• 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cites this paper
• Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI

  2014cites this paper
• Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention.

  2013cites this paper
• Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.

  2013cites this paper
• Ocena warto ści prognostycznej wybranych parametrów klinicznych (Predict Score) oraz testu oporno ści pytek krwi na klopidogrel (Multiplate) w przewidywaniu zdarze ń niedokrwiennych u pacjentów po zabiegach przezskórnej interwencji wie ńcowej.

  2013cites this paper
• Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy

  2013cites this paper
• Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations

  2013cites this paper
• Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.

  2013cites this paper
• Response variability to P2Y12 receptor inhibitors: expectations and reality.

  2013cites this paper
• Platelet Function in Ischemic Heart Disease

  2013cites this paper
• Plättchenfunktionstestung: Erwartung und Realität

  2013cites this paper
• Pharmacology of Antiplatelet Agents

  2013cites this paper
• Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastography

  2013cites this paper
• Pharmacogenomics of Anti-platelet Therapy: How much evidence is enough for clinical implementation?

  2013cites this paper
• Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

  2013cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention

  2013cites this paper
• Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

  2013cites this paper
• Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients wit

  2012cites this paper
• Contemporary use of glycoprotein IIb/IIIa inhibitors

  2012cites this paper
• Role of platelet reactivity in patients undergoing percutaneous coronary intervention

  2012cites this paper
• Platelet function testing in atherothrombotic disease.

  2012cites this paper
• Glycoprotein IIb/IIIa antagonists.

  2012cites this paper
• Spotlight on Eptifibatide in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention

  2012cites this paper
• 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary

  2012cites this paper
• Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

  2012cites this paper
• Newer Pharmaceutical Agents for STEMI Interventions.

  2012cites this paper
• Clopidogrel

  2012cites this paper
• Effect of tailored antiplatelet therapy on periprocedural myonecrosis in patients with diabetes mellitus (from the DM-Verify Now Trial).

  2012cites this paper
• Overview of platelet functional testing methods and their controversial role in the clopidogrel-treated patient

  2012cites this paper
• Antiplatelet Drugs in Coronary Artery Disease

  2012cites this paper
• The effects of clopidogrel loading doses on postoperative bleeding in patients with acute coronary syndrome requiring emergent coronary bypass surgery

  2012cites this paper
• Dual antiplatelet therapy for primary and secondary prevention.

  2012cites this paper
• Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.

  2012cites this paper
• Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention

  2012cites this paper
• Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention

  2012cites this paper
• Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention.

  2012cites this paper
• Antithrombotic Therapy in Non–ST‐Segment Elevation Acute Coronary Syndromes

  2012cites this paper